SG Americas Securities LLC Sells 2,662 Shares of argenx SE (NASDAQ:ARGX)

SG Americas Securities LLC lowered its holdings in argenx SE (NASDAQ:ARGX) by 88.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 337 shares of the company’s stock after selling 2,662 shares during the quarter. SG Americas Securities LLC’s holdings in argenx were worth $183,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Profund Advisors LLC lifted its holdings in argenx by 3.0% in the second quarter. Profund Advisors LLC now owns 973 shares of the company’s stock valued at $418,000 after acquiring an additional 28 shares during the period. Wealth Alliance boosted its holdings in shares of argenx by 4.8% in the second quarter. Wealth Alliance now owns 628 shares of the company’s stock worth $270,000 after buying an additional 29 shares during the last quarter. GAMMA Investing LLC grew its position in argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after buying an additional 40 shares during the period. Toronto Dominion Bank increased its holdings in argenx by 16.5% during the first quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock valued at $119,000 after buying an additional 43 shares during the last quarter. Finally, Sequoia Financial Advisors LLC raised its position in argenx by 3.1% in the second quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company’s stock worth $737,000 after acquiring an additional 52 shares during the period. 60.32% of the stock is owned by institutional investors.

argenx Price Performance

Shares of NASDAQ ARGX opened at $557.92 on Thursday. The stock has a market capitalization of $33.16 billion, a P/E ratio of -98.57 and a beta of 0.63. The business’s 50 day moving average is $533.68 and its two-hundred day moving average is $457.45. argenx SE has a 1-year low of $327.73 and a 1-year high of $571.97.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.34. The business had revenue of $489.43 million for the quarter, compared to analysts’ expectations of $436.66 million. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. During the same quarter in the previous year, the business posted ($1.69) earnings per share. As a group, equities research analysts anticipate that argenx SE will post -0.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on ARGX shares. Wedbush upped their price target on argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. Oppenheimer upgraded argenx from a “market perform” rating to an “outperform” rating and set a $546.00 target price for the company in a research report on Tuesday, July 23rd. Citigroup boosted their price target on argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Robert W. Baird lifted their price objective on shares of argenx from $490.00 to $515.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. Finally, HC Wainwright upped their target price on shares of argenx from $504.00 to $533.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $550.44.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.